Last updated 2026-07-25
TL;DR
Tesamorelin's terminal half life in plasma is short, on the order of 25 to 38 minutes based on population pharmacokinetic modeling in HIV-infected patients and healthy subjects. That's why the FDA-approved regimen is a daily subcutaneous injection rather than a weekly one. A short half life doesn't mean weak effect; it stimulates a pulse of GH and IGF-1 that outlasts the peptide itself.
What is tesamorelin's half life, exactly?
Tesamorelin is cleared from plasma fast. A population pharmacokinetic analysis of tesamorelin in both HIV-infected patients and healthy subjects modeled its disposition using a two-compartment structure and reported a terminal half life in the range of about 25 to 38 minutes, depending on the subgroup and model assumptions [1]. That is short compared to a lot of therapeutic peptides you might have heard of. It is one reason tesamorelin, brand name Egrifta, is dosed once daily rather than once weekly. The drug does its job (triggering the pituitary to release a pulse of growth hormone) and then it's gone from circulation within a couple of hours, well before the next dose is due. A short half life is not a flaw. Tesamorelin is a growth hormone releasing hormone (GHRH) analogue, not growth hormone itself. It needs to show up, bind the GHRH receptor on pituitary somatotrophs, trigger a GH pulse, and clear out. Mimicking the body's own pulsatile GHRH signaling is the point, and a long-acting version would work against that physiology [2].
Why does tesamorelin need daily dosing if it's a growth hormone drug?
Because tesamorelin itself isn't the growth hormone. It's the upstream signal that tells the pituitary to release GH, and that signal is naturally short-lived in the body, so the drug is engineered to mimic a normal physiologic pulse rather than to sit around in the bloodstream for days [2]. The approved regimen for Egrifta SV is a 2 mg subcutaneous injection once daily, taken at the same time each day, typically in the evening on an empty stomach. This schedule stacks up a daily GH pulse that, over months, drives down visceral adipose tissue and raises IGF-1 levels, the downstream marker clinicians use to track whether the drug is doing its job [3] [4]. Because the parent peptide clears in under an hour, missing the injection window by a few hours doesn't build up in your system or cause a rebound problem. It just means you missed that day's GH pulse. For guidance on the practical mechanics of timing a dose around meals and sleep, see our page on best time to take tesamorelin peptide.
How long does tesamorelin stay in your system after an injection?
The parent peptide is largely cleared from plasma within a few hours of a subcutaneous injection, consistent with a half life measured in tens of minutes rather than hours [1]. Peak plasma concentration after a subcutaneous dose is reached quickly, and the compound is degraded by circulating peptidases, the same general clearance route seen with other GHRH analogues. What lingers longer is the downstream effect. IGF-1, the liver-derived hormone that rises in response to the GH pulse tesamorelin triggers, has a much longer circulating half life than tesamorelin itself and is the reason blood levels of IGF-1 climb over the course of days to weeks of daily dosing and are used clinically to confirm a biologic response [3] [4]. So while the peptide is gone from your blood by the next morning, its effect on the GH/IGF-1 axis is cumulative across a treatment course. This distinction, drug half life versus effect duration, matters for anyone trying to reason about detection windows, dosing forgiveness, or why clinical trials measure IGF-1 rather than tesamorelin levels to judge response.
Does a short half life mean tesamorelin is 'weak'?
No. Short half life and weak effect are not the same thing, and tesamorelin's phase 3 trial data make that clear. In pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials in HIV-infected patients with excess abdominal fat, tesamorelin produced a statistically significant reduction in visceral adipose tissue (VAT) compared to placebo, along with sustained safety data through the extension phase [3]. A short-acting GHRH analogue that restores a more normal, pulsatile pattern of GH release is arguably closer to physiologic than a long-acting agent that keeps GH receptors saturated around the clock. The tradeoff is dosing frequency: you get a cleaner physiologic pulse in exchange for a daily injection, rather than a flatter, longer exposure in exchange for less frequent dosing. Reviews of tesamorelin's pharmacology describe this GHRH-mimetic mechanism explicitly, distinguishing it from direct GH replacement [2] [5] [6].
How does tesamorelin's half life compare to other GH-axis peptides?
| Tesamorelin (Egrifta SV) | ~25 to 38 minutes [1] | Once daily, subcutaneous | FDA-approved (HIV lipodystrophy) | |
|---|---|---|---|---|
| Recombinant human GH | Several hours (longer than GHRH analogues) | Once daily, typically | FDA-approved for specific indications | |
| Other GHRH analogues in development | Variable, generally short | Once or twice daily | Mostly investigational | The short half life shared by tesamorelin and other GHRH-class peptides is a design feature tied to their mechanism: they act at the pituitary to provoke a pulse, not to replace the downstream hormone directly [2] [7]. If you're trying to understand where tesamorelin sits relative to other peptides in the compounding and sports-medicine literature, a recent primer for orthopaedic and sports medicine physicians frames tesamorelin alongside other injectable peptide therapies and discusses evidence quality and safety monitoring across the class [8], and a broader review of therapeutic peptides in orthopaedics covers applications and open questions for the category as a whole [9]. |
Here's a rough comparison of half life and dosing frequency across compounds people ask about in the same conversation. These are approximate figures pulled from pharmacology literature and are meant to illustrate the general pattern, not to serve as a dosing guide for unapproved products. | Compound | Approx. plasma half life | Typical dosing frequency | Regulatory status |
What is tesamorelin actually approved for?
Egrifta SV is FDA-approved for one specific indication: reduction of excess visceral adipose tissue in HIV-infected patients with lipodystrophy. That's it. The approval rests on phase 3 randomized, placebo-controlled trial data showing meaningful VAT reduction with an acceptable safety profile over the trial and extension periods [3]. The evidence base beyond that narrow population is a mix of mechanistic and smaller studies, not phase 3 confirmation. Trials and analyses have looked at tesamorelin's effect on hepatic fat and liver enzymes in HIV-associated NAFLD [10] [11], on inflammatory markers tied to visceral fat reduction [12], on fat quality independent of fat quantity [13], and even on neurocognitive outcomes in people with HIV and abdominal obesity [14]. A newer randomized trial specifically evaluated efficacy and safety in people with HIV on integrase inhibitor regimens, a population of particular interest given weight gain associated with that antiretroviral class [15]. None of that expands the FDA label. If you see tesamorelin marketed for general fat loss, anti-aging, or bodybuilding-adjacent goals, understand that's off-label use built on a different, thinner evidence base than the HIV lipodystrophy indication. A meta-analysis of randomized controlled trials in HIV-associated lipodystrophy patients found consistent body composition and hepatic fat benefits with a low rate of drug-related discontinuation across pooled trials [16], but that data describes the approved population, not the general population using the drug off-label.
Does the half life affect how tesamorelin should be reconstituted or stored?
Half life in the body is a separate question from shelf stability of the reconstituted peptide, but people often conflate them. Tesamorelin ships as a lyophilized powder that needs reconstitution with sterile water before injection, and once reconstituted it has a limited window of chemical stability that has nothing to do with its 25 to 38 minute plasma half life [1]. Proper reconstitution technique (correct diluent volume, gentle swirling rather than shaking, refrigeration after mixing) protects the peptide from degradation before it ever gets into your body. Once injected, its short plasma half life is independent of how carefully you handled the vial. For the mechanics of mixing and storing tesamorelin correctly, see our detailed walkthrough on how to reconstitute tesamorelin.
Does the injection site or timing change the effective half life?
Injection site and timing affect absorption rate more than they affect the terminal half life once tesamorelin is in circulation. Subcutaneous injection into abdominal fat is the standard approved route, and pharmacokinetic modeling used in the population PK analysis was based on that administration route in both patients and healthy volunteers [1]. Timing (evening dosing on an empty stomach is the labeled approach) is more about aligning the GH pulse with the body's natural nocturnal GH rhythm and minimizing interference from food-related insulin spikes than about altering clearance kinetics. For a rundown of proper technique and rotation across injection sites, see tesamorelin injection sites and tesamorelin how to inject.
How does the short half life affect dosing schedules and cycle planning?
Because tesamorelin clears fast and doesn't accumulate in plasma, the clinical dosing model is straightforward: one subcutaneous injection daily, same time each day, for as long as the treatment course runs. The phase 3 trials that support the FDA approval ran with daily dosing over 26 and 52 week windows, with extension data supporting continued safety over that period [3]. There's no loading dose and no tapering requirement tied to half life the way you'd see with drugs that have long elimination phases and withdrawal risk. That said, people do ask about running tesamorelin in defined cycles (months on, months off) as opposed to continuous daily use indefinitely, largely for cost and monitoring reasons rather than pharmacokinetic necessity. If that's your question, our page on tesamorelin cycle length covers what the trial data actually supports versus what's anecdotal practice.
What about detection windows, drug testing, and anti-doping context?
Tesamorelin is a GHRH analogue and falls under anti-doping frameworks that prohibit GH-releasing peptides in competitive sport. Detection science in this space has moved toward mass spectrometry methods designed to catch synthetic GHRH analogues in blood or urine, since the short plasma half life of the parent compound makes older immunoassay approaches less reliable for catching use days after injection [17]. For a general reader asking 'how long does tesamorelin stay in your system for a drug test,' the honest answer is: the parent peptide clears within hours, but downstream markers like IGF-1 remain elevated for longer during an active dosing course, and specialized anti-doping labs target both the parent compound and its metabolic signature rather than relying on a simple half life estimate [17].
Where does tesamorelin fit if you're weighing it against other options?
If your reason for reading about tesamorelin's half life is really a question about whether it's the right compound for you, the honest framing is this: tesamorelin has the strongest clinical evidence of any GH-axis peptide on the market today, because it went through FDA phase 3 trials and won approval for a specific indication, visceral fat reduction in HIV-associated lipodystrophy [3]. Every other use case (general fat loss, anti-aging, athletic recovery) is extrapolation from a narrower evidence base, some of it promising (hepatic fat, inflammatory markers, fat quality) [10] [11] [12] [13], some of it still early (neurocognition, integrase-inhibitor populations) [14] [15]. A short half life and daily dosing schedule is the tradeoff for that mechanism and that evidence base. If you're comparing costs of a daily-injection regimen against less frequent options, our breakdown of tesamorelin cost walks through what a real month of treatment runs. We write this as Tesamorelin Co because our job is laying out the evidence plainly, not selling you on off-label enthusiasm the trials don't support. When people are ready to move from research to a real regimen, the responsible path is a provider-reviewed order fulfilled through a licensed pharmacy partner, not a research-chemical vendor with no clinical oversight.
Frequently asked questions
What is the half life of tesamorelin?
Population pharmacokinetic modeling in HIV-infected patients and healthy subjects puts tesamorelin's terminal plasma half life at roughly 25 to 38 minutes, depending on the subgroup and model used [1]. That's short compared to many peptide drugs, which is why it's dosed once daily rather than weekly.
How long does tesamorelin stay in your system after injection?
The parent peptide clears from plasma within a few hours of a subcutaneous dose, consistent with a half life measured in tens of minutes [1]. Its downstream effect on IGF-1, the marker used to confirm biologic response, stays elevated much longer across a daily dosing course [3][4].
Why is tesamorelin injected daily instead of weekly like some peptides?
Tesamorelin is a GHRH analogue meant to mimic the body's own short, pulsatile GHRH signal to the pituitary, not to sit in circulation for days like a long-acting drug [2]. Its short plasma half life (about 25 to 38 minutes) [1] is a design feature of that mechanism, and daily dosing is how the phase 3 trials that won FDA approval were run [5].
Does a short half life mean tesamorelin doesn't work as well?
No. Short half life reflects mechanism, not potency. Pooled phase 3 trial data in HIV-infected patients with excess abdominal fat showed statistically significant visceral fat reduction versus placebo with sustained safety through extension follow-up [5], despite the drug clearing from plasma within hours of each dose.
What is tesamorelin actually FDA-approved to treat?
Egrifta SV is approved specifically to reduce excess visceral adipose tissue in HIV-infected patients with lipodystrophy, based on randomized placebo-controlled phase 3 trial evidence [5]. Any other use, general fat loss, anti-aging, athletic performance, is off-label and rests on a thinner evidence base.
Does missing a dose of tesamorelin cause a rebound or withdrawal effect?
There's no published evidence of a rebound or withdrawal syndrome tied to tesamorelin's short half life. Because the peptide clears within hours and doesn't accumulate, missing a dose mainly means missing that day's GH pulse rather than triggering any adverse reaction.
How does tesamorelin's half life compare to injectable growth hormone?
Recombinant human GH generally has a longer plasma half life than tesamorelin's roughly 25 to 38 minutes [1], though both are typically dosed once daily in their respective approved uses. Tesamorelin works upstream, stimulating the pituitary to release the body's own GH, rather than replacing GH directly [2].
Does injection site change how long tesamorelin lasts in the body?
Injection site can influence absorption speed but the population pharmacokinetic model behind the accepted half life estimate was built on standard subcutaneous abdominal dosing [1]. Site and timing matter more for aligning the GH pulse with the body's natural rhythm than for changing terminal clearance.
Can tesamorelin be detected in a drug test, and for how long?
Anti-doping labs use mass spectrometry methods aimed at synthetic GHRH analogues like tesamorelin because the parent compound's short half life limits older immunoassay detection windows [18]. Elevated IGF-1 during an active dosing course can also serve as an indirect signal, though it's not specific to tesamorelin alone.
Does tesamorelin's short half life mean it's unstable once reconstituted?
No, plasma half life and reconstituted shelf stability are different things. Reconstituted tesamorelin needs refrigeration and has its own handling window based on chemical stability, unrelated to its roughly 25 to 38 minute clearance time once injected [1]. Careless mixing or storage degrades the peptide before it's even in your body.
Is tesamorelin's mechanism the same as taking growth hormone directly?
No. Tesamorelin is a growth hormone releasing hormone (GHRH) analogue that stimulates the pituitary to release the body's own GH in a pulsatile pattern, rather than supplying exogenous GH directly [2][6]. This upstream mechanism is part of why its plasma half life is so short compared to GH itself.
What evidence supports tesamorelin's effect on liver fat, more than visceral fat?
A randomized, double-blind, multicenter trial found tesamorelin reduced hepatic fat in people with HIV and NAFLD [12], and a related study linked visceral fat reduction from tesamorelin to improved liver enzymes [11]. These are separate from the core visceral adipose tissue indication and represent a growing but still secondary evidence line.
Sources
- PubMed, Clinical Pharmacokinetics 2015 (PMID 25358450): Population pharmacokinetic analysis reporting tesamorelin's terminal half life of approximately 25 to 38 minutes in HIV-infected patients and healthy subjects
- PubMed, Nature Reviews Drug Discovery 2011 (PMID 21283099): Tesamorelin acts as a GHRH analogue that stimulates pulsatile pituitary GH release rather than replacing GH directly
- PubMed, The Journal of Clinical Endocrinology and Metabolism 2010 (PMID 20554713): Pooled phase 3 trial data showing tesamorelin's effect on visceral adipose tissue and IGF-1 in HIV-infected patients with excess abdominal fat
- PubMed, Drugs 2011 review (PMID 21668043): Review of tesamorelin's use in HIV-associated lipodystrophy including IGF-1 as a marker of biologic response
- PubMed, Annals of Pharmacotherapy 2012 (PMID 22298602): Description of tesamorelin as a growth hormone-releasing factor analogue for HIV-associated lipodystrophy
- PubMed, Expert Opinion on Investigational Drugs 2009 (PMID 19243281): Early pharmacology review characterizing tesamorelin as a human growth hormone releasing factor analogue
- PubMed, BioDrugs 2011 (PMID 22050344): Spotlight review on tesamorelin mechanism and clinical positioning in HIV-associated lipodystrophy
- PubMed, The American Journal of Sports Medicine 2026 (PMID 41476424): Primer for orthopaedic and sports medicine physicians discussing injectable peptide therapies including evidence and safety monitoring context
- PubMed, JAAOS Global Research & Reviews 2026 (PMID 41490200): Review of therapeutic peptides in orthopaedics covering applications and future directions relevant to peptide comparison
- PubMed, AIDS 2017 (PMID 28832410): Visceral fat reduction with tesamorelin associated with improved liver enzymes in HIV
- PubMed, The Lancet HIV 2019 (PMID 31611038): Randomized double-blind multicenter trial showing tesamorelin's effect on hepatic fat in HIV-associated NAFLD
- PubMed, AIDS 2011 (PMID 21516030): Tesamorelin's effect on inflammatory markers linked to visceral adipose tissue reduction
- PubMed, AIDS 2021 (PMID 33756511): Tesamorelin improves fat quality independent of changes in fat quantity
- PubMed, The Journal of Infectious Diseases 2025 (PMID 39813152): Study of tesamorelin's effects on neurocognitive impairment in persons with HIV and abdominal obesity
- PubMed, AIDS 2024 (PMID 38905488): Trial evaluating efficacy and safety of tesamorelin in people with HIV on integrase inhibitor regimens
- PubMed, Obesity Research & Clinical Practice 2026 meta-analysis (PMID 41545261): Meta-analysis of randomized controlled trials showing body composition and hepatic fat outcomes and safety profile of tesamorelin in HIV-associated lipodystrophy
- PubMed, Drug Testing and Analysis 2021 (PMID 34665524): Advances in detection methods for synthetic GHRH analogs relevant to anti-doping testing of tesamorelin